New antibody drug targets liver cancer in early trial

NCT ID NCT06795022

First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 23 times

Summary

This study tests a new drug called AZD9793 for people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells attack cancer cells. The main goals are to check if the drug is safe and to see if it can shrink tumors. About 304 adults will take part in this early-phase study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    NOT_YET_RECRUITING

    La Jolla, California, 92093, United States

  • Research Site

    NOT_YET_RECRUITING

    Los Angeles, California, 90089, United States

  • Research Site

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21201, United States

  • Research Site

    RECRUITING

    St Louis, Missouri, 63108, United States

  • Research Site

    NOT_YET_RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, 610041, China

  • Research Site

    RECRUITING

    Guangzhou, 510515, China

  • Research Site

    NOT_YET_RECRUITING

    Harbin, 150049, China

  • Research Site

    RECRUITING

    Shanghai, 201114, China

  • Research Site

    NOT_YET_RECRUITING

    Pokfulam, 999077, Hong Kong

  • Research Site

    RECRUITING

    Shatin, 000000, Hong Kong

  • Research Site

    RECRUITING

    Kashiwa, 277-8577, Japan

  • Research Site

    RECRUITING

    Yokohama, 241-8515, Japan

  • Research Site

    NOT_YET_RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    RECRUITING

    Seoul, 5505, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 8035, Spain

  • Research Site

    NOT_YET_RECRUITING

    Pamplona, 31008, Spain

  • Research Site

    RECRUITING

    Taipei, 10002, Taiwan

  • Research Site

    RECRUITING

    Taoyuan, 333, Taiwan

Conditions

Explore the condition pages connected to this study.